Acrux 将来の成長

Future 基準チェック /66

Acrux利益と収益がそれぞれ年間91.6%と34%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に67.8% 91.1%なると予測されています。

主要情報

91.6%

収益成長率

91.1%

EPS成長率

Pharmaceuticals 収益成長	49.3%
収益成長率	34.0%
将来の株主資本利益率	67.8%
アナリストカバレッジ	Low
最終更新日	04 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

業績と収益の成長予測

ASX:ACR - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	14	5	5	5	1
6/30/2026	12	3	3	3	1
6/30/2025	7	-3	-3	-3	1
6/30/2024	5	-6	-5	-4	N/A
3/31/2024	8	-3	-2	-2	N/A
12/31/2023	11	-1	0	1	N/A
9/30/2023	10	-1	0	1	N/A
6/30/2023	8	-1	1	1	N/A
3/31/2023	5	-4	-3	-3	N/A
12/31/2022	2	-8	-6	-6	N/A
9/30/2022	2	-9	-8	-7	N/A
6/30/2022	2	-10	-9	-9	N/A
3/31/2022	1	-10	-11	-10	N/A
12/31/2021	1	-10	-12	-12	N/A
9/30/2021	1	-11	-12	-11	N/A
6/30/2021	1	-13	-12	-11	N/A
3/31/2021	1	-12	-10	-10	N/A
12/31/2020	2	-11	-9	-9	N/A
9/30/2020	1	-10	-9	-9	N/A
6/30/2020	1	-9	-9	-9	N/A
3/31/2020	0	-10	-8	-8	N/A
12/31/2019	-1	-11	-8	-8	N/A
9/30/2019	0	-10	-9	-9	N/A
6/30/2019	1	-8	-10	-10	N/A
3/31/2019	2	-9	-10	-10	N/A
12/31/2018	3	-9	-10	-10	N/A
9/30/2018	3	-12	-8	-8	N/A
6/30/2018	3	-14	-6	-5	N/A
3/31/2018	8	-15	N/A	-2	N/A
12/31/2017	12	-15	N/A	1	N/A
9/30/2017	18	-8	N/A	3	N/A
6/30/2017	24	0	N/A	5	N/A
3/31/2017	24	5	N/A	8	N/A
12/31/2016	25	10	N/A	11	N/A
9/30/2016	27	11	N/A	14	N/A
6/30/2016	29	13	N/A	17	N/A
3/31/2016	29	13	N/A	16	N/A
12/31/2015	29	14	N/A	16	N/A
9/30/2015	27	12	N/A	13	N/A
6/30/2015	25	11	N/A	11	N/A
3/31/2015	25	11	N/A	21	N/A
12/31/2014	24	10	N/A	32	N/A
9/30/2014	39	19	N/A	34	N/A
6/30/2014	54	28	N/A	36	N/A
3/31/2014	55	29	N/A	24	N/A
12/31/2013	55	30	N/A	12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACRは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: ACR今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ACR今後 3 年以内に収益を上げることが予想されます。

収益対市場: ACRの収益 ( 34% ) Australian市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: ACRの収益 ( 34% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACRの自己資本利益率は、3年後には非常に高くなると予測されています ( 67.8 %)。

Acrux 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Recent updates

New major risk - Market cap size

Acrux Limited, Annual General Meeting, Nov 21, 2024

New major risk - Financial position

Full year 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘